Article Text

Review
The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD
  1. Alice Buchan1,
  2. Ruth Bennett2,
  3. Anna Coad3,
  4. Simon Barnes4,
  5. Richard Russell5 and
  6. Ari R Manuel6
  1. 1Medical School, University of Oxford, Oxford, UK
  2. 2Medical School, St Hugh's College, University of Oxford, Oxford, UK
  3. 3Medical School, Queen's College, University of Oxford, Oxford, UK
  4. 4Department of Respiratory Medicine, Oxford University Hospitals, Oxford, UK
  5. 5Department of Respiratory Medicine, Lymington Forest Hospital, Southern Health NHS Trust, Hampshire, UK
  6. 6Oxford Centre for Respiratory Research, Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK
  1. Correspondence to Dr Ari R Manuel; ari.manuel{at}ouh.nhs.uk

Abstract

The presence of cardiovascular comorbidities is frequently associated with poor outcomes in chronic obstructive pulmonary disease (COPD). No clear role has been defined for cardiac biomarkers in acute exacerbations of COPD (AECOPD). The aim of this systematic review was to examine the prognostic value of brain natriuretic peptide (BNP) and troponins in patients with AECOPD. Two independent authors searched the PubMed and Cochrane Library to collect clinical trials, observational studies and meta-analyses studying the prognostic value of cardiac biomarkers in AECOPD. The reference lists of all the included studies were also reviewed. A total of 14 studies were included in the review, of which 10 measured troponins, 7 measured BNP or NT-proBNP, and 3 measured both. Of the studies that used mortality in AECOPD as an end point, some but not all found that elevated BNP and/or troponins were associated with increased mortality. Of the studies that used left ventricular (LV) dysfunction in AECOPD as an end point, all found a significant association between elevated BNP and troponins in the diagnosis of LV dysfunction. In summary, it appears that there may be a link between an elevated level of BNP or NT-proBNP and increased cardiovascular mortality in AECOPD, although the data currently available are not conclusive. The inconsistencies in biomarkers measured, time points of measurements and the variability in outcome measured preclude more robust analysis.

  • HEART FAILURE
  • LUNG 

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: